GlassScriptPhysician profile
Nabila Noor
NPI 1114226396
$7,140.49
in general payments reported to CMS, 2019-2025
7 companies · $2,450 in 2025
The $2,450 reported for 2025 was more than what 85% of Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) providers received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.56 · 2020: $162 · 2021: $353 · 2022: $867 · 2023: $1,351 · 2024: $1,866 · 2025: $2,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,255 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,680 · Travel and Lodging: $733.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,254.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,680.00 |
| Travel and Lodging | $732.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,549.95 | 2021-2025 | Interstim, Signia, Sonicision |
| Boston Scientific Corporation | $1,574.68 | 2019-2025 | Solyx Sis System, Upsylon, Axonics |
| Coloplast Corp | $526.19 | 2023-2025 | Altis, Saffron |
| Axonics, INC. | $203.66 | 2021-2023 | Bulkamid, Axonics |
| Medtronic USA, INC. | $127.53 | 2019-2020 | |
| Urovant Sciences INC | $124.74 | 2022 | |
| Caldera Medical, INC | $33.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabila Noor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.